The beginning of biological treatment era in the atopic dermatitis management.
Unit of Dermatology Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Angelo Massimiliano
AM
D'erme
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; C582203:dupilumab
atopic dermatitis; biologic; dupilumab